Vertex Pharmaceuticals said in its annual report filed recently with the US Securities and Exchange Commission (SEC) that it has licensed VX-210 (formerly Cethrin) for spinal cord injuries from BioAxone Biosciences for $10m up front and up to $90m in development and regulatory milestone payments and license continuation fees.
Boston-based Vertex said it closed the deal with BioAxone, a private company in nearby Cambridge, Massachusetts in October, but it...






